Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
On CNBC's 'Halftime Report Final Trades,' Liz Young, Joshua Brown, Karen Firestone, and Bill Baruch made their stock picks. Young chose Health Care Select Sector SPDR Fund (XLV), noting its recent slight slip. Brown selected Pfizer (PFE), mentioning its December bottom and CEO's commitment to the obesity market despite a drug setback. Firestone picked Autodesk (ADSK), citing a Keybanc analyst's overweight rating and raised price target. Baruch chose AbbVie (ABBV), highlighting an exclusive agreement with Enigma Biomedical and upcoming financial results, with analysts expecting earnings of $2.9 per share on $13.99 billion revenue.
January 19, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Liz Young of BNY Mellon Investment Management named XLV as her final trade, despite a minor slip in price.
XLV was recommended by Liz Young, but the fund's recent minor price slip suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Bill Baruch named AbbVie as his final trade, with an exclusive agreement with Enigma Biomedical and anticipation for Q4 financial results, expected to be strong.
The exclusive agreement and the anticipation of strong Q4 earnings could drive positive momentum for AbbVie's stock in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Karen Firestone chose Autodesk, with Keybanc analyst Jason Celino maintaining an Overweight rating and raising the price target from $245 to $260.
The positive analyst rating and raised price target for Autodesk suggest a bullish short-term outlook for the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 85
POSITIVE IMPACT
Joshua Brown of Ritholtz Wealth Management picked Pfizer, noting its recovery since mid-December and CEO's commitment to the obesity market.
Pfizer's recovery from its December low and the CEO's commitment to the obesity market could positively influence investor sentiment.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80